Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104273 · ClinicalTrials.gov registry record · Phase 2
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
A Phase 2 study of Dementia and Alzheimers Disease, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 376
- Enrollment target
- 20
- Study locations
NCT00104273 is a Phase 2 study of Dementia and Alzheimers Disease that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 376 participants, below the 7,721-participant average among 199 other Dementia trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00104273, a Phase 2 study of Dementia and Alzheimers Disease, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 376 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
Conditions Studied
Interventions
- DRUG Rasagiline
Study Locations (20)
California
- East Bay Region Associates in Neurology - Berkeley
- Margolin Brain Institute - Fresno
- Collaborative Neuroscience Network - Garden Grove
- San Francisco Clinical Research Center - San Francisco
- Neurological Research Institute - Santa Monica
Alabama
- Collaborative Neuroscience Network - Huntsville
- North Alabama Neuroscience Research - Huntsville
Florida
- Premiere Research Institute - West Palm Beach
- North Broward Medical Center/Memory Disorder Center - West Palm Beach
Georgia
- Emory University Wesley Woods Health Center - Altanta
- Dekalb Neurology Associates, LLC - Decatur
Arizona
- Northwest Neurospecialists, PLLC - Tucson
Arkansas
- Clinical Study Centers, LLC - Little Rock
Colorado
- University of Colorado Health Sciences Center - Denver
Illinois
- Radiant Research - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2004-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00104273
The ClinicalTrials.gov registry entry for NCT00104273 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,721-participant average among 199 other Dementia trials with a reported enrollment target (95% lower). The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Dementia appearing as the primary indexed condition, and to 1 intervention - of which Rasagiline is the first listed.
NCT00104273 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT00104273 about?
NCT00104273 is a clinical study titled "Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)". The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
What is the current status of trial NCT00104273?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 376 participants. The study started on 2004-08.
What conditions does trial NCT00104273 study?
This clinical trial studies the following conditions: Dementia, Alzheimers Disease.
What interventions are being tested in trial NCT00104273?
The interventions under investigation include: Rasagiline (DRUG).
Who is sponsoring clinical trial NCT00104273?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00104273 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults
RECRUITING · Phase 2
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Testing the Pain Clinical Practice Guideline
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.